Sino Biopharmaceutical Ltd (1177.HK)
10.34HKD
13 Dec 2019
HK$0.02 (+0.19%)
HK$10.32
HK$10.48
HK$10.48
HK$10.26
27,972,701
51,452,189
HK$12.24
HK$4.53
Latest Key Developments (Source: Significant Developments)
Sino Biopharmaceutical Says Argatroban Injection Obtains Approval By NMPA Of PRC
Dec 12 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ARGATROBAN INJECTION, DEVELOPED BY UNIT HAS OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC. Full Article
Sino Biopharmaceutical "Bendamustine Hydrochloride For Injection" Approved For Drug Registration
Dec 11 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"BENDAMUSTINE HYDROCHLORIDE FOR INJECTION" APPROVED FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC. Full Article
Sino Biopharmaceutical Says "Ademetionine 1,4-Butanedisulfonate For Injection" Obtains Regulatory Approval
Dec 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"ADEMETIONINE 1,4-BUTANEDISULFONATE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION BY NMPA OF PRC. Full Article
Sino Biopharmaceutical Says Esomeprazole Sodium For Injection Obtained Drug Registration Approval Granted By NMPA Of PRC
Nov 27 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ESOMEPRAZOLE SODIUM FOR INJECTION HAS OBTAINED APPROVAL FOR DRUG REGISTRATION GRANTED BY NMPA OF PRC. Full Article
Sino Biopharmaceutical Posts 9-Month Profit Attributable RMB2,255.52 Mln
Nov 26 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::DECLARED PAYMENT OF A QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE FOR THREE MONTHS ENDED 30 SEPTEMBER, 2019.NINE MONTHS REVENUE WAS ABOUT RMB19,320.77 MILLION, INCREASE OF 22.8%.9-MONTH PROFIT ATTRIBUTABLE RMB2,255.52 MILLION, ABOUT 2.5% UP. Full Article
Sino Biopharmaceutical Says Lenalidomide Capsules Gets Approval Of Drug Supplementary Application
Nov 21 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT GETS NOD OF DRUG SUPPLEMENTARY APPLICATION BY NMPA OF CHINA FOR ADDITION OF 2 SPECIFICATIONS OF 5MG AND 10MG. Full Article
Sino Biopharmaceutical Says Fosaprepitant Dimeglumine For Injection Obtains Approval For Drug Registration
Oct 30 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::FOSAPREPITANT DIMEGLUMINE FOR INJECTION OBTAINS APPROVAL FOR DRUG REGISTRATION BY NATIONAL DRUG ADMINISTRATION OF PRC. Full Article
Sino Biopharmaceutical Says Ticagrelor Tablet Obtained Provisional ANDA Approval From U.S. FDA
Oct 14 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::TICAGRELOR TABLET OBTAINED PROVISIONAL APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FROM UNITED STATES FDA. Full Article
Sino Biopharmaceutical Says Azacitidine Obtained Approval For Drug Registration
Oct 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::AZACITIDINE FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.AZACITIDINE IS INDICATED FOR TREATMENT OF ALL SUBTYPES OF MYELODYSPLASTIC SYNDROME AND HAS BEEN GIVEN ORPHAN-DRUG STATUS. Full Article
Sino Biopharmaceutical Says Anlotinib Hydrochloride Capsules Obtains Approval For Drug Registration
Sept 4 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANLOTINIB HYDROCHLORIDE CAPSULES OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC. Full Article
China Resources Gas, Sino Biopharmaceutical to join Hang Seng China Enterprises Index
HONG KONG, Nov 8 Hong Kong's stock index compiler said on Friday that China Resources Gas Group Ltd and Sino Biopharmaceutical Ltd have been selected to join the Hang Seng China Enterprises Index, while two companies will be removed.
Earnings vs. 
Estimates